USPTO Patent Grant for Injectable Pharmaceutical Compositions by Zoetis
Summary
The USPTO has granted patent US12582662B2 to Zoetis Services LLC for injectable pharmaceutical compositions. The patent covers formulations including a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative, designed for effective preservation according to pharmacopoeia standards.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582662B2 to Zoetis Services LLC. This patent covers novel injectable pharmaceutical compositions that include a cyclodextrin complexed with a hydrophobic drug, a preservative, and a co-solvent. The composition is designed to meet stringent preservation criteria outlined in the European Pharmacopoeia and the United States Pharmacopeia for parenteral products.
This patent grant signifies the protection of Zoetis's intellectual property related to this specific drug formulation. While this is a patent grant and not a regulatory rule, it may impact competitors in the pharmaceutical space by limiting their ability to produce or market similar injectable formulations. Compliance officers in the pharmaceutical sector should be aware of this patent when developing or evaluating new injectable drug products, particularly those involving cyclodextrin complexation and specific preservative systems.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Injectable pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent and a preservative
Grant US12582662B2 Kind: B2 Mar 24, 2026
Assignee
Zoetis Services LLC
Inventors
Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
Abstract
The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.
CPC Classifications
A61K 9/0019 A61K 9/08 A61K 31/573 A61K 47/40 A61K 47/10 A61P 23/00
Filing Date
2023-05-26
Application No.
18324305
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.